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Background
Antagonist anti-CD28 antibodies prevent T-cell costimula-
tion and functionally differentiate from CTLA4Ig since
they cannot block CTLA-4 and PDL-1-mediated coinhibi-
tory signals. They demonstrated efficacy in suppressing
effector T cells while enhancing regulatory T cells function
after organ transplantation.
Methods and results
Here we evaluated FR104, a novel antagonist pegylated
Fab’ anti-CD28 monovalent antibody, in xenogeneic
graft-versus-host disease (GVHD) induced in NOD/
SCID mice infused with human PBMC and compared
efficacy with CTLA4Ig molecules. In vitro, FR104 and
CTLA4-Ig (LEA29Y) dose-dependently prevented
human T cell proliferation to a similar extent in mixed
lymphocytes reactions with EC50 at 0.16 and 0.18
micrograms/ml, respectively. IL-2 secretion after stimu-
lation with SEE superantigens was also inhibited in a
similar manner.
NOD/SCID mice adoptively transferred with human
PBMC presented > 80% engraftment after a week and
developed a florid GVHD in the third week due to the
proliferation of xenogeneic human T cells and their infil-
tration into the liver, gut, lung and skin, eventually leading
to weight loss and sacrifice. Treatment of recipient mice
with 5 mg/Kg FR104 biweekly from day 0 to day 25
reduced target organs infiltration by human T cells and
completely prevented weight loss and mortality (p <
0.0001). Mice continued gaining weight and did not suc-
cumb even a month after treatment withdrawal. Flow
cytometry analysis 2 month post engraftment revealed
that FR104 treated mice displayed low level of human cells
engraftment (<10%), indicating that targeting the CD28/
B7 pathway protected from acute GVHD by inhibiting
donor T cell expansion. The therapeutic effect of FR104
was dependent on CTLA-4, since co-administration of
FR104 with blocking anti-CTLA4 antibodies completely
abrogated FR104-mediated protection. This might be
explained by the fact that CTLA-4 signals attenuate T cell
responses independently of CD28. In Contrast, biweekly
administrations of CTLA4-Ig (LEA29Y or Abatacept),
which reduces CD28-CD80/86 costimulation as well as
CTLA-4-CD80/86 coinhibition, was ineffective to protect
mice from severe GVHD, whereas a less intensive protocol
of administration (once a week) was partially effective.
Conclusion
Our data suggests that antagonist anti-CD28 monovalent
antibodies might lead to higher therapeutic indexes, by
sparing CTLA-4, as compared to CD80/CD86 antagonists,
to dampen T cell activation in transplantation.
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